Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Total Non-Current Liabilities (2017 - 2025)

Regen BioPharma (RGBP) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 7.39% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a 7.39% increase, with the full-year FY2025 number at $4.5 million, up 12.63% from a year prior.
  • Total Non-Current Liabilities was $4.3 million for Q4 2025 at Regen BioPharma, down from $4.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $7.8 million in Q3 2021 to a low of -$5.3 million in Q2 2021.
  • A 5-year average of $3.5 million and a median of $4.2 million in 2025 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 96.35% in 2024, then skyrocketed 2806.87% in 2025.
  • Regen BioPharma's Total Non-Current Liabilities stood at $6.6 million in 2021, then dropped by 17.95% to $5.4 million in 2022, then plummeted by 97.14% to $153981.0 in 2023, then skyrocketed by 2530.42% to $4.1 million in 2024, then grew by 7.39% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Total Non-Current Liabilities are $4.3 million (Q4 2025), $4.5 million (Q3 2025), and $4.2 million (Q2 2025).